Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 1409 (115th)

Cancer Drug Parity Act of 2017

referredUnited States· United States Congress· EN

Introduced

7 March 2017

Last action

17 March 2017 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Lance, Leonard [R-NJ-7], Rep. Higgins, Brian [D-NY-26], Rep. Harper, Gregg [R-MS-3], Rep. Foster, Bill [D-IL-11], Rep. Sessions, Pete [R-TX-17], Rep. Garamendi, John [D-CA-8], Rep. Cummings, Elijah E. [D-MD-7], Rep. Wittman, Robert J. [R-VA-1], Rep. Ryan, Tim [D-OH-13], Rep. Poe, Ted [R-TX-2], Rep. Clark, Katherine M. [D-MA-5], Rep. Pingree, Chellie [D-ME-1], Sen. Blackburn, Marsha [R-TN], Rep. King, Peter T. [R-NY-2], Rep. Comstock, Barbara [R-VA-10], Rep. Kildee, Daniel T. [D-MI-5], Rep. Donovan, Daniel M., Jr. [R-NY-11], Rep. Carter, Earl L. "Buddy" [R-GA-1], Rep. DeFazio, Peter A. [D-OR-4], Rep. Guthrie, Brett [R-KY-2], Rep. Pocan, Mark [D-WI-2], Rep. Long, Billy [R-MO-7], Rep. Swalwell, Eric [D-CA-15], Rep. Flores, Bill [R-TX-17], Rep. Maloney, Sean Patrick [D-NY-18], Rep. Murphy, Tim [R-PA-18], Rep. Wasserman Schultz, Debbie [D-FL-25], Rep. Latta, Robert E. [R-OH-5], Rep. MacArthur, Thomas [R-NJ-3], Rep. Kilmer, Derek [D-WA-6], Rep. DesJarlais, Scott [R-TN-4], Rep. Speier, Jackie [D-CA-14], Rep. Grijalva, Raúl M. [D-AZ-7], Rep. Sensenbrenner, F. James, Jr. [R-WI-5], Rep. Peters, Scott H. [D-CA-50], Rep. Fortenberry, Jeff [R-NE-1], Rep. Griffith, H. Morgan [R-VA-9], Rep. Blumenauer, Earl [D-OR-3], Rep. McKinley, David B. [R-WV-1], Rep. Kennedy, Joseph P., III [D-MA-4], Sen. Gallego, Ruben [D-AZ], Rep. Yarmuth, John A. [D-KY-3], Rep. Boyle, Brendan F. [D-PA-2], Rep. Lofgren, Zoe [D-CA-18], Rep. Smucker, Lloyd [R-PA-11], Rep. Moulton, Seth [D-MA-6], Rep. Cartwright, Matt [D-PA-17], Rep. Johnson, Bill [R-OH-6]

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Cancer Drug Coverage Act of 2017 This bill amends the Public Health Service Act to require group and individual health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medication approved by the Food and Drug Administration that is prescribed based on a finding by the treating physician that the medication is medically necessary for cancer treatment and is clinically appropriate in terms of type, frequency, extent site, and duration. To comply with this requirement, health plans may not, for anticancer medications: (1) change or replace benefits to increase out-of-pocket costs; (2) reclassify benefits to increase costs; or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 7 March 2017

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 7 March 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 7 March 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 17 March 2017

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 7 March 2017

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 7 March 2017

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 7 March 2017

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 177 sponsors and actors.

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.